Today: 17 January 2026
Subscribe
Browse Category

Pharmaceutical News News 12 November 2025 - 9 December 2025

Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know

Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know

As of December 9, 2025 Exicure, Inc. (NASDAQ: XCUR) has suddenly moved from obscure micro‑cap to front‑page biotech story. After the company reported positive topline Phase 2 data for its lead drug candidate burixafor in multiple myeloma at the 2025 ASH Annual Meeting on December 8, the stock exploded higher in after‑hours and pre‑market trading. Exicure Below is a comprehensive…
9 December 2025
····
Wave Life Sciences (WVE) Soars 147% on Obesity Drug Breakthrough and $250M Offering: What to Know Before the December 9 Open

Wave Life Sciences (WVE) Soars 147% on Obesity Drug Breakthrough and $250M Offering: What to Know Before the December 9 Open

Wave Life Sciences Ltd. (NASDAQ: WVE) just delivered one of the wildest biotech moves of 2025. On Monday, December 8, 2025, the stock rocketed after the company reported positive Phase 1 obesity drug data for WVE‑007 and simultaneously launched a $250 million equity offering. With the next U.S. trading session set to open on Tuesday, December 9, investors are trying…
9 December 2025
···
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is finishing 2025 with the kind of momentum small-molecule biotechs daydream about. On 8 December 2025, the RNA interference (RNAi) specialist climbed to a new 52‑week high near $69 per share after the company announced it had dosed the first subjects in its Alzheimer’s disease trial ARO‑MAPT and highlighted a string of recent FDA victories…
8 December 2025
···
TNXP Stock Today, 7 December 2025: Price, Latest News and 2026 Forecasts for Tonix Pharmaceuticals

TNXP Stock Today, 7 December 2025: Price, Latest News and 2026 Forecasts for Tonix Pharmaceuticals

Tonix Pharmaceuticals (NASDAQ: TNXP) has quietly turned into one of 2025’s wildest biotech stories: a tiny company that finally won U.S. FDA approval for a fibromyalgia drug after a 15‑year drought, launched it in the U.S., expanded the same molecule into major depressive disorder (MDD), and watched its stock price explode more than 10,000% over the last year. Tonix Pharmaceuticals…
7 December 2025
····
Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025

Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025

Biomea Fusion, Inc. (NASDAQ: BMEA) is back in the spotlight after the company reported long‑term data showing that its experimental diabetes drug icovamenib (formerly BMF‑219) can deliver durable blood‑sugar control many months after patients stop taking it. The new results, presented at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles, pushed Biomea Fusion’s…
5 December 2025
···
Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight. On December 3, 2025, the pharma giant’s share price jumped more than 6% intraday to around $51.32, extending a multi‑day rebound driven by a mix of clinical trial news, AI‑driven R&D milestones, and fresh analyst calls. StockAnalysis At the same time, investors are weighing sizable legal risks and an approaching…
3 December 2025
····
CVS Health Stock on December 2, 2025: Insulin Settlement, Analyst Targets and What’s Next for NYSE: CVS

CVS Health Stock on December 2, 2025: Insulin Settlement, Analyst Targets and What’s Next for NYSE: CVS

As of December 2, 2025, CVS Health Corporation (NYSE: CVS) finds itself in a classic “good news, bad headlines” moment: the stock has pulled back after a strong 2025 rally, the company agreed to a federal settlement over insulin-pen billing, and yet Wall Street’s forecasts still point to further upside. Below is a structured rundown of the latest price action,…
3 December 2025
····
DAX Today: German Stock Market Rebounds as Bayer Soars on Stroke-Drug Success — 24 November 2025

DAX Today: German Stock Market Rebounds as Bayer Soars on Stroke-Drug Success — 24 November 2025

Germany’s stock market started the new week with a relief rally on Monday, 24 November 2025. The DAX 40 clawed back part of last week’s heavy losses as investors cheered a double‑digit surge in Bayer shares and looked past another weak reading on German business sentiment. By mid‑afternoon in Frankfurt, the DAX was trading around 23,200 points, up roughly 0.5–0.7% on the day, after briefly…
24 November 2025
··
InMed Pharmaceuticals (INM) Soars on Alzheimer’s Breakthrough: INM‑901 Study Sparks 20%+ Stock Rally on November 20, 2025

InMed Pharmaceuticals (INM) Soars on Alzheimer’s Breakthrough: INM‑901 Study Sparks 20%+ Stock Rally on November 20, 2025

InMed Pharmaceuticals Inc. (NASDAQ: INM) is back in the spotlight today after a sharp bounce in its share price, driven by fresh preclinical data for its Alzheimer’s disease candidate INM‑901 and heavy speculative trading in the micro‑cap biotech name. On Wednesday, INM shares closed at $1.23, down almost 16% on the day, before surging about 22% after hours to around…
20 November 2025
··
Clearmind Medicine (CMND) Delivers Positive AUD Trial Data Amid New Depression Patent – Nov. 18, 2025

Clearmind Medicine (CMND) Delivers Positive AUD Trial Data Amid New Depression Patent – Nov. 18, 2025

Clearmind Medicine Inc. (NASDAQ: CMND, FSE: CWY0) is back in the spotlight today after releasing positive top-line results from the first cohort of its FDA‑approved Phase I/IIa clinical trial for CMND‑100 in alcohol use disorder (AUD). The update lands just one day after the company highlighted a new Israeli patent filing for a non‑hallucinogenic depression therapy, and as a fresh…
18 November 2025
·
Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025

Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025

Small-cap Israeli biotech rallies after reporting a decade-long cancer‑free outcome in advanced hepatocellular carcinoma and launching enrollment in a pivotal Phase III trial. Shares of Can-Fite BioPharma Ltd. (NYSE American: CANF, TASE: CANF) jumped on Tuesday after the company reported a striking 9‑year overall survival with a complete response in an advanced liver cancer patient treated with its investigational drug…
18 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk (NVO) Today — Nov. 12, 2025: WeightWatchers to Offer Wegovy Pill, Canada Eyes Ozempic Copies, and the Latest Stock Move

Published: November 12, 2025 Summary: WeightWatchers says it will sell Wegovy in a pill once launched WeightWatchers (WW) plans to carry Novo Nordisk’s oral Wegovy, pending U.S. approval, leaning into consumer preference for pills over injections and differentiating from rivals pushing cheaper copycat products. The move follows the company’s bankruptcy exit and dovetails with a broader U.S. pricing framework announced…
12 November 2025
··
1 2 3

Stock Market Today

  • QCLN AI-Generated Signals: Buy near 15.93, stop 15.85
    January 17, 2026, 4:25 PM EST. January 17, 2026 report on First Trust NASDAQ Clean Edge Green Energy ETF (QCLN:CA) shows AI-generated signals. The recommended long plan is to buy near 15.93 with a stop loss at 15.85; no short positions are offered. The piece notes updated AI-generated signals for QCLN:CA and lists Near, Mid, and Long-term ratings as Strong, Weak, and Neutral. It emphasizes checking the timestamp and chart for context. The tone remains factual and concise, delivering actionable points without speculation and in line with market-reporting rhythm.
Go toTop